Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patien...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Format: Artikel
Sprache:English
Veröffentlicht: Frontiers Media S.A. 2024-12-01
Schriftenreihe:Frontiers in Cardiovascular Medicine
Schlagworte:
osimertinib
lung cancer
cardiac toxicity
echocardiogram
EGFR
Online Zugang:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Online

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Ähnliche Einträge